Skip to main content
Volume 1, No 4 - Fall 2001

Volume 1, No 4 - Fall 2001

Table of Contents

Update on Medical Management of Inflammatory Disease: Ulcerative Colitis Treatment Update
Significant advances have been made regarding our understanding of the etiopathogenesis of inflammatory bowel disease. This review focuses on the most recent applications of medical therapy for ulcerative colitis. Therapeutic approaches continue to evolve regarding inductive and maintenance strategies with oral and topical aminosalicylates, systemic and nonsystemic corticosteroids, and cyclosporine and alternative immunomodulators. As further investigations continue to discern microbiological and immunoinflammatory targets, future therapies may include both probiotics and novel biological agents. [Rev Gastroenterol Disord. 2001;1(4):169–176]
Emerging Foodborne Pathogens: Keeping Your Patients and Your Families Safe Gastrointestinal Disorders
Changes in food production and societal pressures have led to a continuing increase in the incidence of foodborne illness. Many pathogens are associated with specific foods, eg, E. coli O157:H7 with hamburgers or Salmonella with eggs. The U.S. Food and Drug Administration has recently approved irradiation for sterilization of meat, but public acceptance of irradiated food is low. Because contaminated foods are seldom detected before they reach store shelves, care in food preparation by professional and home cooks is crucial. [Rev Gastroenterol Disord. 2001;1(4):177–186]
Tegaserod for the Treatment of Constipation-Predominant Irritable Bowel Syndrome New Drug Review
Tegaserod, a potent, partial serotonin 4 receptor (5-HT4) agonist, is an effective agent for the treatment of females with constipation-predominant irritable bowel syndrome. Tegaserod enhances gastric motility, stimulates peristaltic reflux and intestinal secretion, inhibits visceral sensitivity, and/or shortens colonic transit time. This agent may help women who have failed to respond to diet and exercise, laxatives, and other forms of therapy. The optimal dose of tegaserod is 6 mg twice daily and results in decreased number of days per month with pain, bloating, and days without bowel movements. Tegaserod is less effective in males than females in the treatment of constipation-predominant irritable bowel syndrome. Tegaserod is well tolerated. Diarrhea is the most frequent adverse effect. The diarrhea tends to occur most frequently during the first few months of therapy and decreases with continued administration. [Rev Gastroenterol Disord. 2001;1(4):187–198]
Report from the ACG American College of Gastroenterology 66th Annual Scientific Meeting